Pharmaceutical manufacturers of Gabapentin

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Sicor, situated in the northern region of Italy, is a component of the Teva API business and offers a worldwide platform for the production and promotion of APIs for injectable, inhalation, topical, and nasal products. These specialized facilities possess a significant level of skill, manufacturing approximately 60 active pharmaceutical ingredients.

Hengrui Medicine is a prominent pharmaceutical corporation situated in China, focusing on the exploration, production, manufacturing, and marketing of groundbreaking and superior healthcare goods. It underwent restructuring into a joint-stock company in 1997 and was subsequently listed on the Shanghai Stock Exchange under stock code 600276 in 2000. With a market capitalization exceeding 55 billion USD, the company is ranked among the top 30 pharmaceutical firms globally and employs over 21,900 personnel worldwide. Hengrui is recognized as a pioneer in the field of cancer medications, contrast agents, and surgical innovations.

Lonza stands as a prominent supplier in the Pharma&Biotech and Specialty Ingredient markets on a global scale. Our utilization of science and technology allows us to develop a diverse range of products that promote healthier lives for both humans and animals, while also improving overall well-being. The selection includes active pharmaceutical ingredients, stem-cell therapies, drinking water sanitizers, industrial preservatives, microbial control solutions, vitamin B compounds, organic personal care ingredients, and agricultural services and products.

Erregierre, with its two manufacturing facilities, one situated in San Paolo D'Argon (Bergamo) and the other in Sovere (Bergamo), is a privately owned independent company from Italy established in 1974. It is a leading producer of pharmaceutical active components created through synthesis and distributed globally. Erregierre has undergone inspection by the FDA and is deeply dedicated to manufacturing in strict compliance with cGMPs and the highest global quality standards.

Jiangsu Nhwa Pharmaceutical Co., Ltd. was initially founded in 1978. In year 2008, Nhwa listed on the Shenzhen stock exchange with the stock code 002262. NHWA Pharma integrates R&D, production and sales together, as national psychiatric drugs designated unit, national high-tech enterprise, China’s top 100 pharmaceutical enterprises, national intellectual property rights demonstration unit, national "20 years 20 star" medical quality management enterprise star unit, international environmental certification (ISO14000) confirmed enterprise, the first batch of innovative enterprises in Jiangsu province, and vice President unit of China narcotic drug association.

Teva's roots are deeply rooted in the land of Israel since 1901 in Jerusalem. That's when the first chapter was written in the long and unique history of the company, which slowly transformed from a small drug trading house to the largest generic company in the world, improving the health of millions of patients in Israel and around the world every day.

Rakshit Corporation, has a long-standing presence in the field of API production, operating for more than 20 years and possessing facilities that are sanctioned by USFDA, Japan-PMDA, Korean FDA, and multiple approved CEPs. Rakshit stands as the primary global producer of Sildenafil Citrate API and its intermediates, specializing in the production of Erectile Dysfunction APIs. The Rakshit conglomerate is equipped with three manufacturing units that comply with cGMP standards.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

We are one of world’s leading producers of key Active Pharmaceutical Ingredients (APIs) and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector. We endeavour to serve patients by moulding science and technology into therapies to improve health outcomes and people’s lives.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

Glenmark Pharmaceuticals Limited is a global pharmaceutical company based in Mumbai, India. The company focuses on developing and manufacturing generic and innovative drugs. Their therapeutic areas of expertise include dermatology, respiratory, and oncology. They also manufacture high-quality affordable generic products for the US and European markets through Glenmark Life Sciences, an independent unit of Glenmark Pharmaceuticals.

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

Granules India Limited is a rapidly expanding pharmaceutical company with top-notch amenities for APIs, PFIs and Finished Dosages, catering to clients in more than 60 nations. We are dedicated to upholding high standards in production, excellence and client relations. Our main office is situated in Hyderabad, and we also have branches in the United States, United Kingdom, Colombia and China, as well as production facilities in India and China.

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Hua Hai Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company offering a comprehensive range of products and services. They specialize in the production of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, injectables, and oral solutions. Their product portfolio addresses various therapeutic areas such as cardiovascular health, anti-infectives, and central nervous system disorders. The company is committed to innovation through significant investment in research and development, aiming to discover new treatments and enhance existing ones. With state-of-the-art manufacturing facilities adhering to international quality standards, Hua Hai Pharmaceutical is dedicated to delivering high-quality and effective pharmaceutical solutions to global markets.